Introduction: Shanghai Jinsai Biomedical Co., Ltd. (Jinsai Bio) was established in 2000. It is a joint venture between Shanghai Pharmaceutical (Group) Co., Ltd. and American Kangda Biotechnology Holdings Co., Ltd., which is mainly committed to the research, development, production and sales of high-quality recombinant proteins and monoclonal antibodies in the fields of immune diseases and tumor diseases. It is a pioneer and leader in the biomedical industry in China. It is also the first batch of biopharmaceutical enterprises in China and the first one in Shanghai to pass the latest good manufacturing practice (20 10 Revision) (GMP version 20 10) issued by the Ministry of Health. The first product, Qiangke, is a recombinant human tumor necrosis factor receptor-antibody fusion protein for injection, which is a new drug for treating ankylosing spondylitis.
Legal Representative: Ding Bang.
Established: 2000- 1 1-06.
Registered capital:10.40 billion yuan.
Industrial and commercial registration number: 310115400072955
Type of enterprise: limited liability company (Sino-foreign joint venture)
Company address: Innovation Park, Zhangjiang High-tech Development Zone, Shanghai